RYZNEUTA (efbemalenograstim alfa-vuxw)
LEUKOCYTE STIMULATING FACTORS·PREVENTION OF INFECTION IN NON-MYELOID MALIGNANCIES RECEIVING MYELOSUPPRESSIVE TREATMENT
ACROTECH BIOPHA
Indication
Prevention of infection in non-myeloid malignancies receiving myelosuppressive treatment
This indication refers to the prophylactic mitigation of severe, chemotherapy-induced immunosuppression in patients with solid tumors or lymphoid cancers (non-myeloid malignancies) who are receiving regimens cytotoxic to bone marrow. Read more about Prevention of infection in non-myeloid malignancies receiving myelosuppressive treatment
1 drugs 1 manufacturers
Drugs that treat it
Common Prevention of infection in non-myeloid malignancies receiving myelosuppressive treatment therapies.
Filter & compare in the drug finder →Opens the drug finder with Prevention of infection in non-myeloid malignancies receiving myelosuppressive treatment preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThis indication refers to the prophylactic mitigation of severe, chemotherapy-induced immunosuppression in patients with solid tumors or lymphoid cancers (non-myeloid malignancies) who are receiving regimens cytotoxic to bone marrow.
Myelosuppressive agents disrupt hematopoietic cell division, causing a transient but profound nadir in the innate immune system's circulating absolute neutrophil count (severe neutropenia, typically defined as less than 500 cells/mcL).
The resulting depletion of functional neutrophils impairs phagocytic host defenses against endogenous flora and opportunistic pathogens, predisposing patients to life-threatening systemic bacteremia and febrile neutropenia.
Prophylaxis targets this critical window of bone marrow suppression to shorten the duration of severe neutropenia, prevent invasive infectious complications, and minimize chemotherapy dose reductions or treatment delays.
- fda.gov
This indication refers to the prophylactic mitigation of severe, chemotherapy-induced immunosuppression in patients with solid tumors or lymphoid cancers (non-myeloid malignancies) who are receiving regimens cytotoxic to bone marrow
- uspharmacist.com
This indication refers to the prophylactic mitigation of severe, chemotherapy-induced immunosuppression in patients with solid tumors or lymphoid cancers (non-myeloid malignancies) who are receiving regimens cytotoxic to bone marrow Myelosuppressive agents disrupt hematopoietic cell division, causing a transient but profound nadir in the innate immune system's circulating absolute neutrophil count (severe neutropenia, typically defined as less than 500 cells/mcL) The resulting depletion of funct...
- nih.gov
The resulting depletion of functional neutrophils impairs phagocytic host defenses against endogenous flora and opportunistic pathogens, predisposing patients to life-threatening systemic bacteremia and febrile neutropenia Prophylaxis targets this critical window of bone marrow suppression to shorten the duration of severe neutropenia, prevent invasive infectious complications, and minimize chemotherapy dose reductions or treatment delays
Personalize your experience
Follow Prevention of infection in non-myeloid malignancies receiving myelosuppressive treatment and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.